244 related articles for article (PubMed ID: 26364611)
21. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
22. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
24. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
25. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
Vellky JE; McSweeney ST; Ricke EA; Ricke WA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
[TBL] [Abstract][Full Text] [Related]
26. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
27. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
28. DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication.
Ariumi Y; Kuroki M; Abe K; Dansako H; Ikeda M; Wakita T; Kato N
J Virol; 2007 Dec; 81(24):13922-6. PubMed ID: 17855521
[TBL] [Abstract][Full Text] [Related]
29. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
30. Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.
Shukla N; Somwar R; Smith RS; Ambati S; Munoz S; Merchant M; D'Arcy P; Wang X; Kobos R; Antczak C; Bhinder B; Shum D; Radu C; Yang G; Taylor BS; Ng CK; Weigelt B; Khodos I; de Stanchina E; Reis-Filho JS; Ouerfelli O; Linder S; Djaballah H; Ladanyi M
Cancer Res; 2016 Aug; 76(15):4525-34. PubMed ID: 27256563
[TBL] [Abstract][Full Text] [Related]
31. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
32. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
[TBL] [Abstract][Full Text] [Related]
33. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
34. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
35. An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Aiyer RA; Maywald RL; Buford AS; Doolittle DK; Culotta KS; O'Dorisio JE; Ludwig JA
Mol Cancer Ther; 2015 Jul; 14(7):1591-604. PubMed ID: 25964201
[TBL] [Abstract][Full Text] [Related]
36. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.
Erkizan HV; Kong Y; Merchant M; Schlottmann S; Barber-Rotenberg JS; Yuan L; Abaan OD; Chou TH; Dakshanamurthy S; Brown ML; Uren A; Toretsky JA
Nat Med; 2009 Jul; 15(7):750-6. PubMed ID: 19584866
[TBL] [Abstract][Full Text] [Related]
37. Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33.
Tantravedi S; Vesuna F; Winnard PT; Martin A; Lim M; Eberhart CG; Berlinicke C; Raabe E; van Diest PJ; Raman V
Transl Oncol; 2019 Jan; 12(1):96-105. PubMed ID: 30292066
[TBL] [Abstract][Full Text] [Related]
38. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.
Agelopoulos K; Richter GH; Schmidt E; Dirksen U; von Heyking K; Moser B; Klein HU; Kontny U; Dugas M; Poos K; Korsching E; Buch T; Weckesser M; Schulze I; Besoke R; Witten A; Stoll M; Köhler G; Hartmann W; Wardelmann E; Rossig C; Baumhoer D; Jürgens H; Burdach S; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Nov; 21(21):4935-46. PubMed ID: 26179511
[TBL] [Abstract][Full Text] [Related]
39. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.
Crompton BD; Carlton AL; Thorner AR; Christie AL; Du J; Calicchio ML; Rivera MN; Fleming MD; Kohl NE; Kung AL; Stegmaier K
Cancer Res; 2013 May; 73(9):2873-83. PubMed ID: 23536552
[TBL] [Abstract][Full Text] [Related]
40. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
Kukhanova MK; Karpenko IL; Ivanov AV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
